Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Pharmacol Ther. Dec 5, 2025; 16(4): 109177
Published online Dec 5, 2025. doi: 10.4292/wjgpt.v16.i4.109177
Published online Dec 5, 2025. doi: 10.4292/wjgpt.v16.i4.109177
Harnessing postbiotics for liver health: Emerging perspectives
Naveen Jeyaraman, Madhan Jeyaraman, Department of Orthopaedics, ACS Medical College and Hospital, Dr MGR Educational and Research Institute, Chennai 600077, Tamil Nadu, India
Naveen Jeyaraman, Madhan Jeyaraman, Arulkumar Nallakumarasamy, Department of Regenerative Medicine, Agathisha Institute of Stemcell and Regenerative Medicine, Chennai 600030, Tamil Nadu, India
Tejaswin Mariappan, Department of Community Medicine, Government Stanley Medical College and Hospital, Chennai 600001, Tamil Nadu, India
Arulkumar Nallakumarasamy, Department of Orthopaedics, Jawaharlal Institute of Postgraduate Medical Education and Research, Karaikal 605006, Puducherry, India
Preethi Subramanian, Department of Radiation Oncology, Apollo Proton Cancer Centre, Chennai 600113, Tamil Nadu, India
Priyadarshini T, Department of Anaesthesiology, ACS Medical College and Hospital, Dr MGR Educational and Research Institute, Chennai 600077, Tamil Nadu, India
Vinnisa Nithiakala Vetrivel, Department of Obstetrics and Gynecology, Vinayaka Mission Medical College and Hospital, Karaikal 609609, Puducherry, India
Author contributions: Jeyaraman N contributed to proofreading; Jeyaraman N, Mariappan T, Nallakumarasamy A, and Vetrivel VN contributed to manuscript writing; Jeyaraman N, Mariappan T, Subramanian P, and T P contributed to acquiring clinical data and performing the data analysis; Jeyaraman M helped in manuscript revision, contributed to conceptualization and administration; all authors have agreed to the final version to be published and agree to be accountable for all aspects of the work.
Conflict-of-interest statement: All authors declare no conflict of interests in publishing the manuscript.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Madhan Jeyaraman, MD, PhD, Researcher, Department of Orthopaedics, ACS Medical College and Hospital, Dr MGR Educational and Research Institute, Velap
Received: May 6, 2025
Revised: July 1, 2025
Accepted: November 5, 2025
Published online: December 5, 2025
Processing time: 218 Days and 7 Hours
Revised: July 1, 2025
Accepted: November 5, 2025
Published online: December 5, 2025
Processing time: 218 Days and 7 Hours
Core Tip
Core Tip: Postbiotics, bioactive compounds produced by beneficial microbes, have emerged as promising therapeutic agents for liver diseases linked to gut microbiome dysbiosis. They offer anti-inflammatory, immunomodulatory, and antioxidant benefits, aiding in conditions like metabolic dysfunction-associated steatotic liver disease, liver cirrhosis, and hepatocellular carcinoma. Limited research underscores the need for extensive studies to unravel their classification, mechanisms, and potential in combating microbial and metabolic disorders.